Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS
PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers
JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities
PK exposure demonstrated TRACTr activation with lack of TCE accumulation
No treatment-emergent ADA titers observed
Janux to host virtual investor event today at 4:00 PM Eastern Time
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica
